Source: ERJ Open Res, 4 (1) 00121-2017; 10.1183/23120541.00121-2017



Rating:

Share or cite this content

Citations should be made in the following way:
Vissagan Gopalakrishnan, Amanda M. Jones, Patricia Julien-Williams, Tania Machado, Robert L. Danner, Jeffrey J. Swigris, Robert Paine, Jay N. Lozier, Joel Moss. Pseudoneutropenia in lymphangioleiomyomatosis (LAM) patients receiving sirolimus: evaluation in a 100 patient cohort. ERJ Open Res, 4 (1) 00121-2017; 10.1183/23120541.00121-2017

Member's Comments

No comment yet.

Related content which might interest you: Early-onset therapy with sirolimus helps to improve prognosis of patients with lymphangioleiomyomatosis (LAM) Source: International Congress 2019 – Towards a better understanding of rare diffuse parenchymal lung diseases Year: 2019 Retrospective evaluation of our cohort of CTD-ILD RA patients treated with Rituximab: 5 years follow up. Source: Virtual Congress 2021 – Clinical evolution, management and outcomes of patients with rare diffuse parenchymal lung diseases Year: 2021 The course of COVID-19 in pulmonary sarcoidosis patients, receiving methotrexate Source: Virtual Congress 2021 – Moving forward in various aspects of sarcoidosis Year: 2021 Initial combination therapy with ambrisentan (AMB) and tadalafil (TAD) in treatment naïve patients with pulmonary arterial hypertension (PAH): Efficacy and safety in the AMBITION study intent to treat (ITT) population Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Is pulmonary rehabilitation (PR) an effective therapy in lymphangioleiomyomatosis (LAM)? Source: Annual Congress 2012 - The best posters in pulmonary rehabilitation and chronic care Year: 2012 The experience of use plasmaferesis in complex treatment in patients with pulmonary sarcoidosis (PS) Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis Year: 2008 Prolonged sirolimus therapy in advanced pulmonary lymphangioleiomyomatosis; a multicenter French experience Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012 Safety and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) receiving commonly used concomitant medications Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease Year: 2012 One year follow-up of patients with idiopathic pulmonary fibrosis treated with immunosuppressive therapy Source: Annual Congress 2007 - Considerations in the management of idiopathic pulmonary fibrosis and other interstitial lung diseases Year: 2007 Long-term response to prednisone in newly treated patients with pulmonary sarcoidosis Source: Virtual Congress 2021 – Better understanding of sarcoidosis: new keys Year: 2021 The effectiveness of plasmaferesis in patients with relapsing and progressing course of pulmonary sarcoidosis (5 years follow-up) Source: Annual Congress 2010 - Clinical issues in diffuse parenchymal lung disease Year: 2010 Comparison of post renal transplant tuberculosis cases receiving conventional immunosupressive therapy and mycophenolat mofetil (MMF) and/or tacrolimus (TAC) Source: Eur Respir J 2003; 22: Suppl. 45, 157s Year: 2003 Impact of bisphosphonate (BP) use on lung function decline and treatment response in patients (pts) with idiopathic pulmonary fibrosis (IPF) Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020 Prospective cohort study of patients complaining of high pressure with CPAP/APAP (PAP) who switch to bi-level PAP (VAuto) as second-line therapy: POP-IN study Source: International Congress 2019 – Treatment of continuous positive airway pressure and monitoring of its effects Year: 2019 Patterns of discontinuation in the long-term RECAP study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis (IPF): the INSTAGE trial Source: International Congress 2018 – Clinical news in idiopathic interstitial pneumonias Year: 2018 Treatment of idiopathic pulmonary fibrosis (IPF) with nintedanib: an experience from the compassionate use program (CUP) in Estonia Source: International Congress 2017 – Clinical problems in lung diseases Year: 2017 Docetaxel as second-line chemotherapy (CT) in advanced non small cell lung cancer(NSCLC) patients (pts): does it really work? Source: Eur Respir J 2003; 22: Suppl. 45, 31s Year: 2003 Optimizing treatment for life-threatening hemoptysis: a prospective follow-up of 101 patients over 1 year Source: Eur Respir J 2007; 30: Suppl. 51, 559s Year: 2007 Are SABA-reliant asthma patients receiving adequate ICS therapy? A nationwide cohort study in Sweden (HERA) Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019